Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Mark Perlmutter

Hand Surgery Rocky Mount, NC Medical Doctor

NPI 1467540534 CMS profile 1031410

110 Patrick Ct, Rocky Mount, NC 27804

Open in the dashboard

General payments

$5,807

77 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Mark Perlmutter of Rocky Mount, NC is reported in the CMS Open Payments database as having received $5,807 across 77 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 69th percentile of Hand Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $168 10
2024 General $54 2
2023 General $60 3
2022 General $196 10
2021 General $3,812 25
2020 General $1,379 18
2019 General $139 9

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Mark Perlmutter
  • Hand Surgery median
  • Middle half of Hand Surgery
  • National median

In program year 2025, general payments to Mark Perlmutter were reported at $168. Among 1,842 Hand Surgery profiles paid that year, the median was $270 and the middle half received between $102 and $1,118.

Show as a table
Year Mark Perlmutter Hand Surgery median Middle half National median
2019 $139 $383 $106–$1,905 $163
2020 $1,379 $172 $51–$1,268 $114
2021 $3,812 $263 $71–$1,591 $132
2022 $196 $336 $87–$1,938 $149
2023 $60 $233 $81–$1,114 $160
2024 $54 $258 $88–$1,203 $164
2025 $168 $270 $102–$1,118 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Arthrex, Inc. $3,353 18 payments
  2. SouthTech Orthopedics $1,502 5 payments
  3. Nevro Corp. $144 9 payments
  4. IBSA Pharma Inc. $140 7 payments
  5. Collegium Pharmaceutical, Inc. $97 5 payments
  6. Scilex Pharmaceuticals Inc. $75 4 payments
  7. Salix Pharmaceuticals, a division of Bausch Health US, LLC $65 4 payments
  8. Radius Health, Inc. $42 2 payments
  9. Zimmer Biomet Holdings, Inc. $40 3 payments
  10. Kerecis Limited $40 1 payment
  11. Other $308 19 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Education $2,400 2 payments
  2. Travel and Lodging $2,261 11 payments
  3. Food and Beverage $1,121 63 payments
  4. Entertainment $24 1 payment
Products named General payments · program years 2019–2025
  1. Licart $140 7 payments
  2. Tirosint Endocrinology $119 6 payments
  3. Flector $79 4 payments
  4. Omnia $73 5 payments
  5. RELISTOR $65 4 payments
  6. BELBUCA $57 3 payments
  7. Senza Spinal Cord Stimulation System $57 3 payments
  8. Tymlos $42 2 payments
  9. TIROSINT Endocrinology $41 2 payments
  10. EBI Bone Healing System $40 3 payments
  11. Other $756 38 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 10 drugs

Part D claims

679

Median for Orthopedic Surgery: 203

Drug cost

$6,078

Median for Orthopedic Surgery: $1,433

Branded share of claims

22.7%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Omeprazole Generic 205 $1,761
Celecoxib Generic 57 $1,550
Ketorolac Tromethamine Generic 72 $1,233
Ondansetron Odt Ondansetron Brand 132 $448
Gabapentin Generic 30 $382
Scopolamine Generic 23 $286
Dexamethasone Generic 99 $171
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 22 $159
Tramadol Hcl Generic 27 $71
Meloxicam Generic 12 $16

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 169 billing codes

Paid by Medicare

$245,270

Of which drugs: $5,029

Medicare patients

599

Average age 73

Services billed

5,721

355 women, 244 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 72%
Diabetes 37%
Chronic kidney disease 32%
Ischemic heart disease 29%
Depression 23%
COPD 18%
Osteoporosis 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 174 1,340 $997
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 51 152 $782

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

77 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Hand Surgery in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record